Dr. Kruter studies the effects of various drugs and treatments in managing side effects experienced by cancer patients, particularly those undergoing chemotherapy. His research investigates conditions such as chemotherapy-induced nausea and pain, focusing on how combinations of treatments, like specific anti-nausea medications, can improve patients' quality of life. He also examines healthcare policy impacts, such as how the Affordable Care Act has influenced breast cancer treatment practices and patient outcomes.
Key findings
In a study of patients undergoing strong chemotherapy, those treated with olanzapine and fosaprepitant experienced 7.4% better control of nausea compared to those treated with olanzapine alone.
After the Affordable Care Act was implemented, there was a rise in earlier stage breast cancer diagnoses, with fewer patients requiring mastectomies and more receiving radiation treatments.
Among 600 women with early-stage breast cancer, 40% of those taking naproxen and 43% taking loratadine reported bone pain, compared to 47% who received no treatments.
Frequently asked questions
Does Dr. Kruter study chemotherapy-induced nausea?
Yes, he examines how different drugs can help prevent nausea and vomiting in patients undergoing chemotherapy.
What treatments has Dr. Kruter researched for breast cancer?
He has researched the efficacy of medications like olanzapine, naproxen, and loratadine in managing side effects for breast cancer patients receiving chemotherapy.
Is Dr. Kruter's work relevant to early-stage breast cancer patients?
Absolutely, his research focuses on improving treatments and reducing pain for women with early-stage breast cancer during chemotherapy.
How has healthcare policy impacted cancer treatment according to Dr. Kruter's research?
His study shows that the Affordable Care Act led to more patients being diagnosed earlier, resulting in fewer mastectomies and more appropriate radiation treatments.
What can patients expect from Dr. Kruter's findings?
Patients can expect insights into better management of treatment side effects, which can significantly improve their comfort and quality of life during cancer therapy.
Publications in plain English
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
2023
The oncologist
Navari RM, Le-Rademacher J, Smieliauskas F, Ruddy KJ, James Saphner T +10 more
Plain English This study looked at how well an anti-nausea drug, olanzapine, worked with or without an additional drug called fosaprepitant in preventing nausea and vomiting in patients undergoing strong chemotherapy. Researchers found that patients who received olanzapine along with fosaprepitant had 7.4% better results in avoiding nausea for five days after treatment compared to those who didn’t get fosaprepitant. This finding is important because it suggests that removing fosaprepitant from treatment may lead to more nausea and less effective symptom control for patients undergoing these types of chemotherapy.
Who this helps: This helps patients receiving strong chemotherapy treatments.
The impact of the affordable care act on breast cancer care in the USA: A multi-institutional analysis.
2019
The breast journal
Maxwell J, Shats O, Aldridge J, Lyden E, Krie A +12 more
Plain English This study looked at how the Affordable Care Act (ACA) affected breast cancer care in the United States by comparing data from hospitals before and after its implementation. After the ACA was enacted, patients tended to be older and more likely to have Medicaid insurance. Notably, there was a rise in imaging tests performed, which led to more patients being diagnosed at earlier stages of cancer, resulting in fewer mastectomies and more patients receiving radiation treatment.
Who this helps: This benefits breast cancer patients and healthcare providers.
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
2018
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Kirshner JJ, McDonald MC, Kruter F, Guinigundo AS, Vanni L +5 more
Plain English This study looked at whether taking naproxen or loratadine before chemotherapy could reduce bone pain caused by the drug pegfilgrastim in women with early-stage breast cancer. Among the 600 patients, about 40% of those taking naproxen and 43% taking loratadine reported bone pain, compared to 47% who received no treatment. While none of the treatments significantly reduced pain compared to each other, loratadine was noted to cause fewer side effects and might be a better option for managing this pain.
Who this helps: This is beneficial for women with early-stage breast cancer undergoing chemotherapy, helping them manage bone pain more effectively.
Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck.
1992
Investigational new drugs
Kruter F, Eisenberger M, Sinibaldi V, Engstrom C, Jacobs M +4 more
Plain English This study looked at the effects of a drug called 6-thioguanine given through an IV for five days to patients with advanced head and neck cancer. Out of fifteen patients, none showed any improvement, and the average time until the disease worsened was 58 days, while patients lived about 227 days on average. The researchers found that the treatment caused significant blood-related side effects, leading them to conclude that this drug should not be used for this type of cancer.
Who this helps: This helps doctors understand which treatments are ineffective for these patients.
Rudolph M Navari Jennifer Le-Rademacher Fabrice Smieliauskas Kathryn J Ruddy Thomas James Saphner Heshan Liu Elizabeth Harlos Adedayo A Onitilo Karthik Giridhar Preet Paul Singh
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.